Caterina Antonaglia | Public Health & Epidemiology | Best Review Paper Award

Published on by Medical Lab Scientist

Best Review Paper Award

Caterina Antonaglia
Affiliation University of Trieste
Country Belgium
Scopus ID 55578828100
Documents 23
Citations 307
h-index 11
Subject Area Public Health & Epidemiology
Event Medical Lab Scientist Awards
ORCID 0000-0001-6494-3962

Caterina Antonaglia

University of Trieste is associated with the scholarly profile of Caterina Antonaglia, whose published work contributes to the fields of public health and epidemiology. The recognition represented by the Best Review Paper Award acknowledges the importance of comprehensive literature synthesis, methodological rigor, and evidence-based interpretation within contemporary biomedical research. The profile presented below summarizes institutional affiliation, research output, scientific impact, and award relevance within the framework of the Medical Lab Scientist Awards.[1]

Abstract

The Best Review Paper Award recognizes scholarly work that systematically evaluates existing evidence, identifies knowledge gaps, and contributes to scientific understanding through rigorous analysis. Caterina Antonaglia’s research profile reflects sustained engagement with public health and epidemiological topics, supported by peer-reviewed publications and measurable citation impact. Review-based scholarship plays a fundamental role in guiding future investigations and informing evidence-based decision-making across medical and laboratory sciences.[2]

Keywords

Public Health, Epidemiology, Systematic Review, Evidence Synthesis, Biomedical Research, Scientific Communication

Introduction

Review papers constitute an essential component of academic literature because they integrate findings from multiple investigations and provide critical perspectives on evolving research topics. In epidemiology and public health, review studies support policy development, improve methodological transparency, and facilitate interdisciplinary collaboration. Recognition through academic awards emphasizes the value of comprehensive scholarship and analytical interpretation.[3]

Research Profile

According to publicly available author metrics, Caterina Antonaglia has produced twenty-three indexed documents and has received more than three hundred citations, resulting in an h-index of eleven. The profile reflects active engagement in public health and epidemiological research and demonstrates the influence of scholarly publications within the scientific community.[1]

Research Contributions

Development of evidence-based reviews in public health research. Contribution to epidemiological knowledge synthesis and interpretation. Promotion of methodological transparency in biomedical investigations. Support for interdisciplinary collaboration across healthcare disciplines.

Publications

The publication record includes representative review articles focused on epidemiological methodologies, evidence synthesis, and public health research, along with papers indexed in international bibliographic databases and scholarly repositories, reflecting contributions to interdisciplinary healthcare and biomedical sciences.[1]

Research Impact

Citation indicators, publication volume, and interdisciplinary relevance provide quantitative measures of research influence. Review articles often receive broad academic attention because they consolidate fragmented findings and create foundations for future studies. The citation record associated with this profile demonstrates engagement by researchers working in related domains.[1]

Award Suitability

The Best Review Paper Award emphasizes analytical depth, scholarly rigor, and contribution to scientific advancement. Evaluation criteria commonly include originality, methodological quality, citation influence, and relevance to contemporary biomedical challenges. The documented publication record and measurable impact indicators align with the objectives of the Medical Lab Scientist Awards program.[5]

Conclusion

Academic review articles remain indispensable for translating research findings into coherent scientific knowledge. Through contributions to public health and epidemiology, Caterina Antonaglia’s scholarly profile illustrates the significance of evidence synthesis and critical evaluation. Recognition through the Best Review Paper Award reflects the continuing importance of high-quality review scholarship in advancing medical and laboratory sciences.[2]

References

  1. Elsevier. (2026). Scopus author details: Caterina Antonaglia, Author ID 55578828100. Scopus.
    https://www.scopus.com/pages/authors/55578828100
  2. Sleep Medicine. (2026). Women and obstructive sleep apnea syndrome: Can we finally ask the right questions? The OSAF study.
    https://doi.org/10.1016/j.sleep.2026.108932
  3. Healthcare. (2026). Optimizing CPAP Adherence in Obstructive Sleep Apnea: A Narrative Review of Practical Strategies for Everyday Clinical Care.
    https://doi.org/10.3390/healthcare14152328
  4. Respiratory Medicine. (2026). Sex differences in low arousal threshold in obstructive sleep apnea.
    https://doi.org/10.1016/j.rmed.2025.108625
  5. Medical Lab Scientist Awards. (2026). Award criteria and evaluation guidelines.
    https://medicallabscientist.com/

Maria Gheorghe | Public Health & Epidemiology | Best Researcher Award

Published on by Medical Lab Scientist

Ms. Maria Gheorghe | Public Health & Epidemiology | Best Researcher Award

Director at Pfizer Inc, Romania

Maria Gheorghe is an accomplished expert in health economics and outcomes research (HEOR) with over 14 years of impactful contributions spanning academia, research institutions, and the pharmaceutical industry. Currently serving as Director of Global HTA, Value and Evidence at Pfizer Inc., she has led high-stakes initiatives in antimicrobial resistance, oncology, and vaccine access. Her career reflects a commitment to evidence-based healthcare, strategic market access, and policy transformation at both national and international levels.

profile

orcid

Education

Maria Gheorghe holds a PhD in Health Economics from Erasmus University Rotterdam, where her doctoral work focused on quantitative approaches to monitoring population quality of life, particularly modeling and evaluating health utility data. She also earned an MSc in Applied Mathematics from Delft University of Technology, where she explored advanced Bayesian methods in reservoir simulation. Her academic foundation began with a BSc in Economics, majoring in Cybernetics, Statistics, and Economics, from the Academy of Economic Studies in Bucharest. This combination of mathematical rigor and economic insight has uniquely positioned her to address complex health policy challenges.

Professional Experience

Maria’s career is marked by a progressive trajectory through key roles in industry and academia. Since June 2022, she has led global value and evidence generation strategies at Pfizer for the launch of EMBLAVEO, a next-generation anti-infective. She has been instrumental in coordinating cross-functional global teams and external stakeholders to secure optimal pricing and reimbursement frameworks across various healthcare systems. Prior to this, she contributed to oncology strategy, particularly supporting the global launch of Talzenna + Xtandi for metastatic castration-sensitive prostate cancer (mCSPC). From 2019 to 2022, she held national responsibilities as Health & Value Manager for Pfizer Romania, where she led the market access strategies for Eliquis, Paxlovid, and hospital brands. Earlier roles at Sanofi in market access and public affairs allowed her to shape reimbursement policies and build influential partnerships. Her formative experience as a researcher at Erasmus School of Health Policy and Management laid the groundwork for her methodical and evidence-driven approach to health economics.

Research Interests

Maria’s research interests span real-world evidence, cost-effectiveness modeling, and antimicrobial resistance policy. She is particularly passionate about bridging the gap between epidemiological modeling and reimbursement systems, advancing HTA frameworks that integrate the societal value of novel therapeutics. Her recent work leverages machine learning and big data to inform pricing models for anti-infectives and supports innovative reimbursement agreements based on value-based healthcare principles.

Awards and Recognition

Maria has earned significant recognition for her strategic leadership and research excellence. She played a pivotal role in the UK’s innovative reimbursement scheme for anti-infectives—a global case study in AMR policy reform. She has also been commended internally at Pfizer for her contributions to cross-functional evidence planning and real-world data integration. Her academic achievements include graduating top of her MSc cohort at Delft and securing competitive research roles across Europe.

Selected Publications

Gheorghe M. et al. (2020). Economic evaluation of novel antibiotics: challenges and recommendations. Value in Health. Cited by 34 articles.

Gheorghe M. et al. (2019). Modeling transmission in cost-effectiveness studies: the case of antimicrobial resistance. Pharmacoeconomics. Cited by 21 articles.

Gheorghe M. et al. (2018). Quality of life trajectories in chronic disease populations: a longitudinal analysis. Health Economics. Cited by 16 articles.

Gheorghe M. et al. (2017). Bayesian approaches in population health modeling. Journal of Health Services Research & Policy. Cited by 12 articles.

Gheorghe M. et al. (2016). Comparative methods for population-level health utility estimation. European Journal of Health Economics. Cited by 10 articles.

Gheorghe M. et al. (2015). A meta-analysis of EQ-5D values across disease groups. International Journal of Technology Assessment in Health Care. Cited by 9 articles.

Gheorghe M. et al. (2014). Cost-effectiveness of vaccines in emerging markets. Vaccine. Cited by 17 articles.

Conclusion

Maria Gheorghe embodies the qualities of a top-tier researcher—intellectual excellence, strategic impact, innovation in health policy, and a commitment to public health advancement. Her accomplishments in research, leadership in evidence-based strategies, and contributions to global health challenges make her a highly deserving recipient of the Best Researcher Award.